Trial Condition(s):
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.
:- Have hypertension- Are currently taking antihypertensive medications- Have had natural menopause at least 1 year prior to screening- Must require hormone therapy in the opinion of the investigator
No Exclusion Criteria Available
Locations | Status |
---|
A multicenter, double-blind, randomized, placebo-controlled study comparing 3 continuous oral Angeliq (drospirenone 3 mg/17ß-estradiol 1 mg, drospirenone 2 mg /17ß-estradiol 1 mg, drospirenone 1 mg /17ß-estradiol 1 mg) combinations and 17ß-estradiol (1 mg) with placebo for a treatment period of 8 weeks on ambulatory and office cuff blood pressure in postmenopausal women with Stage 1 or Stage 2 essential hypertension
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Factorial Assignment
Trial Arms:
5